Global private equity and venture capital news and research

Posts Tagged ‘oncology’

4 November 2015

Abraaj buys two oncology businesses

blood-732298_640 Dubai-based The Abraaj Group has tapped its second North Africa Fund to acquire a majority stake in two oncology businesses.

2 January 2015

NEA, KPCB back $28.5m 3-V Biosciences Series D

cancer juno Venture capital firms including New Enterprise Associates and Kleiner Perkins Caufield & Byers have backed a $28.5m Series D financing round for pharmaceutical business 3-V Biosciences.

14 November 2014

Anti-cancer business Blueprint Medicines bags $50m VC-backed Series C

blueprint_real_estate_170sq A string of venture capital firms have backed a $50m Series C financing round for cancer treatment developer Blueprint Medicines.

25 June 2014

Oncology focus pays off, says Nextech CEO $

alps For life sciences venture firms, it is riskier to have a broad focus than targeting a specific segment of the sector, according to Nextechinvest founding partner and CEO Alfred Scheidegger.

23 June 2014

Definiens raises €15m to expand into digital tissue diagnostics

analysis European venture capital firm Wellington Partners has led a €15m growth financing round for German digital pathology image analysis and digital tissue diagnostics specialist Definiens.

15 October 2013

Auven exits cancer drug developer Spirogen to AstraZeneca arm MedImmune

news_spirogen_molecule_lrg Drug-focused private equity investor Auven Therapeutics has sold cancer-targeting pharmaceutical developer Spirogen to MedImmune in a deal worth up to $240m.

15 October 2013

Wellington Partners backs €34m Series D round for kidney cancer vaccine maker Immatics

biomed_lrg European venture capital firm Wellington Partners was among backers of a €34m Series D financing round for German anti-cancer vaccine maker Immatics Biotechnologies.

3 October 2013

OrbiMed joins Aisling in $33m Loxo Oncology Series A round

Founding Loxo Oncology investor Aisling Capital has upped its commitment to the cancer treatment biopharma business by taking part in a $33m Series A financing round.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016